Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Income from Continuing Operations (2021 - 2025)

Aligos Therapeutics filings provide 5 years of Income from Continuing Operations readings, the most recent being 19881000.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 75.8% to 19881000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 24193000.0, a 81.56% increase, with the full-year FY2025 number at 24193000.0, up 81.56% from a year prior.
  • Income from Continuing Operations hit 19881000.0 in Q4 2025 for Aligos Therapeutics, up from 31537000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 43088000.0 in Q1 2025 to a low of 82150000.0 in Q4 2024.
  • Median Income from Continuing Operations over the past 5 years was 22420500.0 (2022), compared with a mean of 23372950.0.
  • The widest YoY moves for Income from Continuing Operations: up 223.59% in 2025, down 413.44% in 2025.
  • Aligos Therapeutics' Income from Continuing Operations stood at 37714000.0 in 2021, then soared by 41.97% to 21886000.0 in 2022, then fell by 27.44% to 27892000.0 in 2023, then plummeted by 194.53% to 82150000.0 in 2024, then skyrocketed by 75.8% to 19881000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 19881000.0 (Q4 2025), 31537000.0 (Q3 2025), and 15863000.0 (Q2 2025) per Business Quant data.